Vet Comp Orthop Traumatol 2017; 30(01): 1-7
DOI: 10.3415/VCOT-16-02-0026
Original Research
Schattauer GmbH

Influence of calcium salts and bovine thrombin on growth factor release from equine platelet-rich gel supernatants

Carlos E. Giraldo
1   Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia
María E. Álvarez
1   Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia
Jorge U. Carmona
1   Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia
› Author Affiliations
Financial support: This project was supported by a grant of the Vicerrectoría de Investigaciones y Postgrados of the Universidad de Caldas, Manizales, Colombia.
Further Information

Publication History

Received: 15 February 2016

Accepted: 09 August 2016

Publication Date:
26 December 2017 (online)


Objective: To compare five activation methods in equine platelet-rich plasma (PRP) by determination of platelet-derived growth factor BB (PDGF-BB) and transforming growth factor beta 1 (TGF-β1) concentrations in platelet-rich gel (PRG) supernatants.

Methods: Platelet-rich plasma from 20 horses was activated by calcium chloride (CC), calcium gluconate (CG), bovine thrombin (BT), and their combinations, BTCC and BTCG. Both growth factor concentrations in PRG supernatants were measured by ELISA and compared with plasma and platelet ly-sates (PL) over time.

Results: Growth factor concentrations were significantly lower in plasma and higher for all PRG supernatants. Platelet lysates contained a significantly lower concentration of PDGF-BB than PRG supernatants and a significantly higher concentration of TGF-β1 than PRG supernatants. Clots from PRP activated with sodium salts were more stable over time and had significant growth factor release, whereas CC produced gross salt deposition. Significant correlations were noticed for platelet with leukocyte concentrations in PRP (rs: 0.76), platelet counts in PRP with TGF-β1 concentrations in PRG supernatants (rs: 0.86), platelet counts in PRP with PDGF-BB concentrations in PRG super-natants (rs: 0.78), leukocyte counts in PRP with TGF-β1 concentrations in PRG supernatants (rs: 0.76), and PDGF-BB concentrations with activating substances (rs: 0.72).

Clinical significance: Calcium gluconate was the better substance to induce PRP activation. It induced growth factor release free from calcium precipitates in the clots. Use of BT alone or combined with calcium salts was not advantageous for growth factor release.

  • References

  • 1 Argüelles D., Carmona JU., Climent F.. et al Autologous platelet concentrates as a treatment for musculoskeletal lesions in five horses. Vet Rec 2008; 162: 208-211.
  • 2 Carmona JU., Argüelles D., Climent F.. etal. Autologous platelet concentrates as a treatment of horses with osteoarthritis: a preliminary pilot clinical study. J Equine Vet Sci 2007; 27: 167-170.
  • 3 Castelijns G., Crawford A., Schaffer J.. et al. Evaluation of a filter-prepared platelet concentrate for the treatment of suspensory branch injuries in horses. Vet Comp Orthop Traumatol 2011; 24: 363-369.
  • 4 Waselau M., Sutter WW., Genovese RL.. et al. Intralesional injection of platelet-rich plasma followed by controlled exercise for treatment of midbody suspensory ligament desmitis in Standardbred racehorses. J Am Vet Med Assoc 2008; 232: 1515-1520.
  • 5 Iacopetti I., Perazzi A., Ferrari V.. et al. Application of platelet-rich gel to enhance wound healing in the horse: A case report. J Equine Vet Sci 2012; 32: 123-128.
  • 6 López C., Carmona JU.. Platelet-rich plasma as an adjunctive therapy for the management of a severe chronic distal limb wound in a foal. J Equine Vet Sci 2014; 34: 1128-1133.
  • 7 Monteiro SO., Lepage OM., Theoret CL.. Effects of platelet-rich plasma on the repair of wounds on the distal aspect of the forelimb in horses. Am J Vet Res 2009; 70: 277-282.
  • 8 Dohan Ehrenfest DM., Bielecki T., Mishra A.. et al. In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol 2012; 13: 1131-1137.
  • 9 Carmona JU., López C., Sandoval JA.. Review of the currently available systems to obtain platelet related products to treat equine musculoskeletal injuries. Rec Pat Reg Med 2013; 3: 148-159.
  • 10 Textor JA., Tablin F.. Activation of equine platelet-rich plasma: comparison of methods and characterization of equine autologous thrombin. Vet Surg 2012; 41: 784-794.
  • 11 Argüelles D., Carmona JU., Pastor J.. et al. Evaluation of single and double centrifugation tube methods for concentrating equine platelets. Res Vet Sci 2006; 81: 237-245.
  • 12 Sutter WW., Kaneps AJ., Bertone AL.. Comparison of hematologic values and transforming growth factor-β and isulinlike growth factor concentrations in platelets concentrates obtained by use of buffy coat and apheresis methods from equine blood. Am J Vet Res 2004; 65: 924-930.
  • 13 Giraldo CE., Álvarez ME., Carmona JU.. Effects of sodium citrate and acid citrate dextrose solutions on cell counts and growth factor release from equine pure-platelet rich plasma and pure-platelet rich gel. BMC Vet Res 2015; 11: 60.
  • 14 McCarrel TM., Minas T., Fortier LA.. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am 2012; 94: e143.1-e143.8.
  • 15 Carmona JU., López C.. Autologous platelet concentrates as a treatment for shoulderinjury in a horse. J Equine Vet Sci 2011; 31: 506-510.
  • 16 Ramachandran R., Hollenberg MD.. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. British J Pharmacol 2008; 153 (Suppl. 01) S263-S282.
  • 17 Offermanns S.. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293-1304.
  • 18 Hu H., Forslund M., Li N.. Influence of extracellular calcium on single platelet activation as measured by whole blood flow cytometry. Thrombosis Res 2005; 116: 241-247.
  • 19 Davies TA., Drotts DL., Weil GJ.. et al. Cytoplasmic Ca2+ is necessary for thrombin-induced platelet activation. J Biol Chem 1989; 264: 19600-19606.
  • 20 Cenni E., Savarino L., Perut F.. et al. Background and rationale of platelet gel in orthopaedic surgery. Musculoskelet Surg 2010; 94: 1-8.
  • 21 Zimmermann R., Arnold D., Strasser E.. et al. Sample preparation technique and white cell content influence the detectable levels of growth factors in platelet concentrates. Vox Sang 2003; 85: 283-289.
  • 22 Textor JA., Norris JW., Tablin F.. Effects of preparation method, shear force, and exposure to collagen on release of growth factors from equine platelet-rich plasma. Am J Vet Res 2011; 72: 271-278.
  • 23 McCarrel T., Fortier L.. Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. J Orthop Res 2009; 27: 1033-1042.
  • 24 Giraldo CE., López C., Álvarez ME.. et al. Effects of the breed, sex and age on cellular content and growth factor release from equine pure-platelet rich plasma and pure-platelet rich gel. BCM Vet Res 2013; 9: 29.
  • 25 Vendruscolo CP., Carvalho AdM., Moraes LF.. et al. Evaluating the effectiveness of different protocols for preparation of platelet rich plasma for use in equine medicine. Pesq Vet Bras 2012; 32: 106-110.
  • 26 Penha-Goncalves MN., Onions DE., Nicolson L.. Cloning and sequencing of equine transforming growth factor-beta 1 (TGF beta-1) cDNA. DNA Seq 1997; 7: 375-378.
  • 27 Donnelly BP., Nixon AJ., Haupt JL.. Nucleotide structure of equine platelet-derived growth factor-A and -B and expression in horses with induced acute tendinitis. Am J Vet Res 2006; 67: 1218-1225.
  • 28 Gornall AG., Bardawill CJ., David MM.. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949; 177: 751-766.
  • 29 Faul F., Erdfelder E., Buchner A.. et al. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149-1160.
  • 30 Dunkel B., Bolt DM., Smith RK.. et al. Stimulus-dependent release of tissue-regenerating factors by equine platelets. Equine Vet J 2012; 44: 346-354.
  • 31 Jiménez-Aristizabal RF., Prades M., Carmona JU.. Preliminary evaluation of platelet rich fibrin clot (L-PRF) in horses. Proceedings of the Annual Science Meeting of the European College of Veterinary Surgeons 2012. July 5-7 Barcelona, Spain: 63.
  • 32 Textor JA., Tablin F.. Intra-articular use of a platelet-rich product in normal horses: clinical signs and cytologic responses. Vet Surg 2013; 42: 499-510.
  • 33 Ortel TL., Mercer MC., Thames EH.. et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001; 233: 88-96.
  • 34 Randleman Jr CD ., Singla NK., Renkens KL.. et al. Persistence of antibodies to the topical hemostat bovine thrombin. J Am Coll Surg 2010; 211: 798-803.